Every material Form 8-K SkinHealth Systems Inc. has filed with the SEC since October 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
SkinHealth Systems reported third-quarter 2026 net sales of $69.2 million, down 2.1% from a year earlier, as delivery system sales fell. Net loss narrowed to $0.9 million from $11.0 million, and adjusted EBITDA rose to $13.4 million from $8.9 million. The company also updated its fiscal 2026 guidance to net sales of $281 million to $287 million and adjusted EBITDA of $48 million to $50 million, citing continued pressure on sales.
Q3 2026 net sales were $69.2 million versus $70.7 million in Q3 2025; delivery systems placed fell to 798 from 875.
Net loss was $0.9 million in Q3 2026 versus $11.0 million in Q3 2025; adjusted EBITDA was $13.4 million versus $8.9 million.
Updated fiscal 2026 guidance: net sales of $281 million to $287 million and adjusted EBITDA of $48 million to $50 million.
Cash, cash equivalents and restricted cash were about $112 million at September 30, 2026, versus about $233 million at December 31, 2025, after the 2026 notes were retired.
SkinHealth Systems Inc. (SKIN) will combine every 20 shares of its Class A common stock into one share, effective at 12:00 a.m. ET on October 14, 2026, with trading on a split-adjusted basis on the Nasdaq Capital Market starting that day under the same ticker. The company said the split is intended to help it regain compliance with Nasdaq's $1.00 minimum bid price requirement, and that it does not change any stockholder's percentage ownership, except for cash paid in lieu of fractional shares.
Ratio: 1-for-20; outstanding shares expected to fall from approximately 130.3 million to approximately 6.5 million, based on shares outstanding as of October 7, 2026
Stockholders approved the split at a special meeting on September 22, 2026; the Board set the 1-for-20 ratio the same day
New CUSIP number 88331L306; ticker remains SKIN; convertible notes due 2028 conversion rate adjusted proportionately
The company states the split may not produce a sustained rise in share price, may reduce trading liquidity, and may not restore Nasdaq compliance
SkinHealth Systems Inc. repaid in full the remaining $103,235,000 principal of its 1.25% convertible senior notes on September 30, 2026, plus $645,218.75 in accrued interest, ahead of their October 1, 2026 maturity. The repayment satisfied and discharged the indenture, releasing the company from its remaining obligations under it, except for provisions that survive by their terms.
Principal repaid: $103,235,000 on September 30, 2026
Accrued and unpaid interest paid: $645,218.75
Notes were issued September 14, 2021 and were set to mature October 1, 2026
Indenture satisfied and discharged; U.S. Bank National Association acted as trustee
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every SkinHealth Systems Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →